EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 544 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR New reports show staff shortages continue to hold back cancer care June 9, 2022 Should alcohol marketing be dropped from televised sport? August 27, 2021 Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... June 17, 2024 Researchers Create Modified Antibodies to Target RAS and p53 in Cancer April 2, 2021 Load more HOT NEWS Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds ESMO Asia Congress 2023, 1-3 December 2023, Singapore Reflections on My First Year as NCI Director
